GBT Announces New Employment Inducement Grants
05 October 2020 - 11:00PM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today
announced that on October 1, 2020, the compensation committee
of GBT’s board of directors granted 20 new employees options to
purchase an aggregate of 12,000 shares of the company’s common
stock with a per share exercise price of $57.96 and restricted
stock units for an aggregate of 93,950 shares of the company’s
common stock. These awards were made under GBT’s Amended and
Restated 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement
material to the employees entering into employment with the company
in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted
pursuant to the terms of the Plan. The Plan was adopted by GBT’s
board of directors in January 2017 and has been amended and
restated from time to time.
About Global Blood TherapeuticsGlobal Blood
Therapeutics (GBT) is a biopharmaceutical company dedicated to
the discovery, development, and delivery of life-changing
treatments that provide hope to underserved patient communities.
Founded in 2011, GBT is delivering on its goal to transform the
treatment and care of sickle cell disease (SCD), a lifelong,
devastating inherited blood disorder. The company has introduced
Oxbryta® (voxelotor), the first FDA-approved treatment that
directly inhibits sickle hemoglobin polymerization, the root cause
of red blood cell sickling in SCD. GBT is also advancing its
pipeline program in SCD with inclacumab, a p-selectin inhibitor in
development to address pain crises associated with the disease. In
addition, GBT’s drug discovery teams are working on new targets to
develop the next generation of treatments for SCD. To learn more,
please visit www.gbt.com and follow the company on
Twitter @GBT_news.
Contact Information:Steven Immergut (investors
and media)650-410-3258simmergut@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2024 to May 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Global Blood Therapeutics Inc (NASDAQ): 0 recent articles
More News Articles